GAIA BioMedicine
Developing a new platform to generate nk-like cells that can effectively eliminate solid tumors without the need for genetic modification.
Launch date
Employees
Market cap
-
Enterprise valuation
€5—8m (Dealroom.co estimates Nov 2020.)
Fukuoka Fukuoka Prefecture (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| N/A | JPY50.0m | Seed | |
| N/A | JPY50.0m | Seed | |
| N/A | JPY100m | Series A | |
| N/A | JPY380m | Series A | |
$6.0m | Series A | ||
| N/A | JPY190m | Series B | |
$920k | Grant | ||
JPY1.3b | Series B | ||
| Total Funding | €20.7m | ||